255 related articles for article (PubMed ID: 32507066)
1. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis.
Uppal SK; Kearns DG; Chat VS; Han G; Wu JJ
J Dermatolog Treat; 2022 Mar; 33(2):626-636. PubMed ID: 32507066
[TBL] [Abstract][Full Text] [Related]
2. Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
Ratchataswan T; Banzon TM; Thyssen JP; Weidinger S; Guttman-Yassky E; Phipatanakul W
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1053-1065. PubMed ID: 33685604
[TBL] [Abstract][Full Text] [Related]
3. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
Uppal SK; Chat VS; Kearns DG; Wu JJ
J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
[TBL] [Abstract][Full Text] [Related]
4. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
Yang N; Chen Z; Zhang X; Shi Y
BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy of systemic treatments for atopic dermatitis.
Seger EW; Wechter T; Strowd L; Feldman SR
J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535
[TBL] [Abstract][Full Text] [Related]
6. Biological therapies for atopic dermatitis: An update.
Deleanu D; Nedelea I
Exp Ther Med; 2019 Feb; 17(2):1061-1067. PubMed ID: 30679974
[TBL] [Abstract][Full Text] [Related]
7. Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
Simpson EL; Merola JF; Silverberg JI; Reich K; Warren RB; Staumont-Sallé D; Girolomoni G; Papp K; de Bruin-Weller M; Thyssen JP; Zachariae R; Olsen CK; Wollenberg A
Br J Dermatol; 2022 Dec; 187(6):888-899. PubMed ID: 36082590
[TBL] [Abstract][Full Text] [Related]
8. The role of lebrikizumab in the treatment of atopic dermatitis in the adult population.
Prajapati S; Fardos M; Desai AD; Feldman SR
Immunotherapy; 2023 Sep; 15(13):981-991. PubMed ID: 37401345
[TBL] [Abstract][Full Text] [Related]
9. An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults.
Picone V; Vallone Y; Patruno C; Napolitano M
Expert Rev Clin Pharmacol; 2023; 16(12):1239-1248. PubMed ID: 38054328
[TBL] [Abstract][Full Text] [Related]
10. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A; Blauvelt A; Guttman-Yassky E; Worm M; Lynde C; Lacour JP; Spelman L; Katoh N; Saeki H; Poulin Y; Lesiak A; Kircik L; Cho SH; Herranz P; Cork MJ; Peris K; Steffensen LA; Bang B; Kuznetsova A; Jensen TN; Østerdal ML; Simpson EL;
Br J Dermatol; 2021 Mar; 184(3):437-449. PubMed ID: 33000465
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis.
Loh TY; Hsiao JL; Shi VY
J Asthma Allergy; 2020; 13():109-114. PubMed ID: 32104006
[TBL] [Abstract][Full Text] [Related]
12. Selective IL-13 inhibitors for the treatment of atopic dermatitis.
Gonçalves F; Freitas E; Torres T
Drugs Context; 2021; 10():. PubMed ID: 33889195
[TBL] [Abstract][Full Text] [Related]
13. Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018.
Werfel T
Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):432-437. PubMed ID: 30095475
[TBL] [Abstract][Full Text] [Related]
14. Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.
Butala S; Castelo-Soccio L; Seshadri R; Simpson EL; O'Shea JJ; Bieber T; Paller AS
J Allergy Clin Immunol Pract; 2023 May; 11(5):1361-1373. PubMed ID: 36948491
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of biologics in atopic dermatitis.
Wu J; Guttman-Yassky E
Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
[No Abstract] [Full Text] [Related]
16. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.
Snast I; Reiter O; Hodak E; Friedland R; Mimouni D; Leshem YA
Am J Clin Dermatol; 2018 Apr; 19(2):145-165. PubMed ID: 29098604
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
Silverberg JI; Thyssen JP; Fahrbach K; Mickle K; Cappelleri JC; Romero W; Cameron MC; Myers DE; Clibborn C; DiBonaventura M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1797-1810. PubMed ID: 33991374
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
[TBL] [Abstract][Full Text] [Related]
20. Review of Tralokinumab in the Treatment of Atopic Dermatitis.
Singh R; Taylor A; Shah MA; Strowd LC; Feldman SR
Ann Pharmacother; 2023 Mar; 57(3):333-340. PubMed ID: 35730479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
